Mustang Bio receives Nasdaq delist notice but granted extension; interim CFO resigns, CEO takes over

MUSTANG BIO, INC.

Nasdaq Staff issued delist determination on Nov 13, 2024 for non-compliance with bid price rule.
Nasdaq Hearings Panel granted extension to Jan 31, 2025 for bid price and Feb 18, 2025 for equity rule compliance.
James Murphy resigned as Interim CFO on Nov 12, 2024; no disagreement involved.
President/CEO Manuel Litchman appointed Interim CFO effective Nov 15, 2024; previously held role in Dec 2023-Jan 2024.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

James Murphy

Interim Chief Financial Officer

MBIO · MUSTANG BIO, INC.

Effective: 2024-11-12
Successor: Manuel Litchman
Filed: November 15, 2024, 6:59 PM ET

On November 12, 2024, James Murphy resigned as the Company’s Interim Chief Financial Officer.

Appointed (interim)

Manuel Litchman

Interim Chief Financial Officer

MBIO · MUSTANG BIO, INC.

Effective: 2024-11-15
Filed: November 15, 2024, 6:59 PM ET

On November 15, 2024, the Company’s Board of Directors (the “Board”) appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company’s Interim Chief Financial Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Murphy resigned as Interim Chief Financial Officer at MUSTANG BIO, INC..

Action: resigned
Role: Interim Chief Financial Officer

Exact text from the filing

On November 12, 2024, James Murphy resigned as the Company’s Interim Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Manuel Litchman was appointed as Interim Chief Financial Officer at MUSTANG BIO, INC..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On November 15, 2024, the Company’s Board of Directors (the “Board”) appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company’s Interim Chief Financial Officer, effective immediately.

View on SEC.gov

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-119756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.